Dishman Carbogen Amcis Rating Cut; Company Highlights Performance Gains

OTHER
Whalesbook Logo
AuthorSimar Singh|Published at:
Dishman Carbogen Amcis Rating Cut; Company Highlights Performance Gains
Overview

Dishman Carbogen Amcis has clarified a credit rating downgrade by India Ratings to 'A' (long-term) and 'A1' (short-term) with a negative outlook. The company emphasized that the downgrade does not reflect its improving business and financial performance, pointing to enhanced net leverage and strengthening EBITDA margins. The rating agency cited persistently high debt levels and contracting margins as reasons for the revision.

Dishman Carbogen Amcis Clarifies Rating Downgrade Amidst Performance Improvements

Net leverage improved to 3.18x (from 3.92x in FY25); EBITDA margins strengthened to 25.68% (from 19.35% in FY25).
Reader Takeaway: Net leverage improved significantly; negative rating outlook signals ongoing financial pressures.

What just happened (today’s filing)

Dishman Carbogen Amcis Ltd has issued a clarification following a credit rating downgrade by India Ratings & Research. The rating agency revised the company's India credit facilities to 'IND A' for long-term and 'IND A1' for short-term, with a 'Negative' outlook. This action, dated February 18, 2026, was met with a clarification from the company on February 23, 2026.

The company stated that the downgrade does not reflect its improving business and financial performance. It highlighted key positive trends, including an improvement in its consolidated net leverage ratio and strengthening EBITDA margins.

Why this matters

A credit rating downgrade can increase borrowing costs for a company and signal potential financial stress to investors. The negative outlook suggests that the rating agency foresees potential challenges ahead.

Dishman Carbogen Amcis's clarification aims to reassure stakeholders by emphasizing internal performance improvements, suggesting the rating action may not fully capture the company's operational trajectory.

The backstory (grounded)

Dishman Carbogen Amcis, a pharmaceutical CDMO, has faced scrutiny over its financial leverage. In April 2024, India Ratings had affirmed its ratings at 'IND A+'/Stable. However, the recent downgrade stems from persistently high net adjusted leverage, which stood at 3.92x in FY25 and is expected to remain above 3x in FY26 on a consolidated basis.

Standalone leverage presents a more concerning picture, reaching 9.94x in FY25. The rating agency also noted contracting EBITDA margins, which have fallen below levels seen before the company's European Directorate for the Quality of Medicines & HealthCare (EDQM) issues.

Adding to margin pressures, the company's new French facility, operational since FY25, reported an EBITDA loss of EUR 9.8 million in FY25. To address these concerns, Dishman Carbogen Amcis plans to raise up to ₹10 billion via a Qualified Institutional Placement (QIP) or preferential shares to repay high-cost debt and improve its leverage metrics.

What changes now

  • Borrowing Costs: A lower credit rating may lead to higher interest rates on future debt, increasing financial expenses.
  • Investor Sentiment: The downgrade could impact investor confidence, although the company's rebuttal aims to mitigate this.
  • Financial Flexibility: High leverage and a negative outlook can restrict the company's ability to undertake significant new debt-funded initiatives.

Risks to watch

  • Sustained Leverage: The ability to bring down consolidated net leverage below 3x and improve standalone metrics remains critical.
  • Margin Recovery: Achieving sustained improvement in EBITDA margins, especially from the French facility, is key.
  • Capital Raise Execution: Successful completion of the planned ₹10 billion capital raise will be crucial for deleveraging.

Peer comparison

Dishman Carbogen Amcis operates in the competitive Contract Development and Manufacturing Organisation (CDMO) and Active Pharmaceutical Ingredient (API) space. Peers like Syngene International and Laurus Labs are also significant players in India's pharmaceutical outsourcing sector. While Syngene is known for its broad R&D and manufacturing capabilities, Laurus Labs has a strong focus on API and intermediate production. Divi's Laboratories is another major Indian API player. The comparison highlights the intense competition and the need for strong financial health and operational efficiency in this sector.

Context metrics (time-bound)

  • Consolidated Net Leverage stood at 3.18x as of September 30, 2025, down from 3.92x as of March 31, 2025.
  • EBITDA Margins (excluding France/India operations) for the six months ended September 30, 2025, were 25.68%, an increase from 19.35% for the full fiscal year 2025.

What to track next

  • Capital Raise Progress: Monitor the timeline and success of the planned ₹10 billion QIP or preferential share issuance.
  • Debt Reduction: Track the actual reduction in total debt and net leverage ratios post-capital raise.
  • EBITDA Margin Improvement: Watch for sustained margin growth across segments, especially the French facility's performance.
  • Standalone Performance: Evaluate the turnaround and credit metrics of the standalone Indian operations.
  • Future Rating Reviews: Observe how India Ratings and other agencies reassess the company's credit profile in subsequent reviews.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.